Effective Angioedema Treatment: From Prophylaxis to Novel Therapeutic Options
Understanding Hereditary, Idiopathic, and Acquired Angioedema
Angioedema is a medical condition characterized by localized swelling of the deeper layers of the skin and mucous membranes. There are three main types of angioedema based on its underlying cause - hereditary angioedema (HAE), idiopathic angioedema, and acquired angioedema.
Hereditary angioedema (HAE) is caused due to a deficiency or dysfunction of C1-esterase inhibitor (C1-INH), a protein that regulates certain inflammatory pathways. Symptoms typically appear in childhood or adolescence. Idiopathic angioedema has no identified triggering factor and accounts for majority of cases. Acquired angioedema is caused due to medications, medical conditions, or autoimmune disorders that reduce C1-INH levels similar to HAE.
Treatment Goals and Considerations
The principal goals in Angioedema Treatment include promptly stopping an ongoing attack, preventing future attacks, managing long-term control, and improving patient's quality of life. Treatment options used will depend on the type and severity of attacks, previous treatment responses, and patient preferences.
Safety and adherence are also important factors to consider given that angioedema treatments involve lifelong management. Cost and insurance coverage posed due to the expensive specialty therapies available further influence treatment decisions. The complexity of the condition requires coordinated care from specialists.
Prophylactic Therapies
Regular use of prophylactic medications can effectively reduce attack frequency in HAE patients. The options include C1-INH concentrates administered via intravenous or subcutaneous routes. A new oral drug, berotralstat, that inhibits plasma kallikrein is also approved for prophylaxis.
These targeted therapies are highly effective and convenient treatment options. However, their high drug acquisition costs and need for refrigeration to preserve shelf life may pose challenges. Anti-fibrinolytics like tranexamic acid are less expensive alternatives but are associated with risks like blood clots. Prophylactic attacks are ideally driven by attack history, severity of symptoms, impact on quality of life etc.
Acute Attack Therapies
For treating acute attacks, available treatment approaches include C1-INH replacement therapy, bradykinin receptor antagonists, and analgesics. C1-INH products have emerged as the treatment of choice owing to their superior efficacy demonstrated in clinical trials. Icatibant, a bradykinin B2 receptor antagonist, offers a non-blood derived option.
Attack therapies are promptly administered at onset of symptoms to achieve significantly reduced time to resolution compared to supportive management alone. Home therapy using self-administered C1-INH concentrates enables faster treatment and reduces delays. The option chosen will depend on factors like availability, cost, route of administration etc.
Emerging Treatment Modalities
Novel therapies targeting different pathogenic mechanisms are in the pipeline to address unmet needs in angioedema management. These include agents targeting plasmakallikrein, antibodies inhibiting lipopolysaccharide binding protein, and BDKRB2 gene silencing techniques.
A subcutaneous C1-INH preparation and an oral plasma kallikrein inhibitor are under regulatory review. Other avenues being explored are immunomodulation therapies to induce C1-INH tolerance, hematopoietic stem cell therapy to replace defective cells, and gene therapy techniques to replace defective genes. Such targeted investigational options hold promise to deliver significant improvements in effectiveness, quality of life, and therapy flexibility.
Get More Insights On- Angiodema Treatment Market
Get This Report In Japanese
Get This Report In Korean
About Author:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )